Melatonin reduces the mortality of severely-infected COVID-19 patients
Abstract
SARS-CoV-2 has ravaged the population of the world for two years. Scientists have not yet identified an effective therapy to reduce the mortality of severe COVID-19 patients. In a single-center, open-label, randomized clinical trial, it was observed that melatonin treatment lowered the mortality rate by 93% in severely-infected COVID-19 patients compared with the control group (see below). This is seemingly the first report to show such a huge mortality reduction in severe COVID-19 infected individuals with a simple treatment. If this observation is confirmed by more rigorous clinical trials, melatonin could become an important weapon to combat this pandemic.
References
2. Mahase E (2021) Covid-19: UK becomes first country to authorise antiviral molnupiravir. BMJ 375: n2697, doi:10.1136/BMJ.N2697.
3. Pfizer’s Novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study | Pfizer Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate (accessed on Nov 24, 2021).
4. Mughal MS, Kaur IP, Jaffery AR, Dalmacion DL, Wang C, Koyoda S, Kramer VE, Patton CD, Weiner S, Eng MH, et al. (2020) COVID-19 patients in a tertiary US hospital: Assessment of clinical course and predictors of the disease severity. Respir. Med. 172: 106130. doi:10.1016/J.RMED.2020.106130.
5. Mughal MS, Kaur IP, Wang C, Alhashemi R, Buemio A, Patton CD, Granet KM (2021) Variation in clinical characteristics, outcomes, and mortality of hospitalized patients with COVID-19 during the second wave of the pandemic: a single-center experience. J. Investig. Med. 69 (8): 1479-1482, jim-2021-001876, doi:10.1136/JIM-2021-001876.
6. Hasan ZT, Atrakji DMQYMAA, Mehuaiden DAK (2021) The Effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. Int. J. Infect. Dis. 114: 79-84. doi:10.1016/J.IJID.2021.10.012.
7. Ramlall V, Zucker J, Tatonetti N (2020) Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv. Prepr. Serv. Heal. Sci. doi:10.1101/2020.10.15.20213546.
8. Castillo RR, Quizon GRA, Juco MJM, Roman ADE, Leon D.G, Punzalan FER, Guingon RBL, Morales DD, Tan D-X, Reiter RJ, Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Res. 3: 297–310, doi:10.32794/MR11250063.
9. Alizadeh Z, Keyhanian N, Ghaderkhani S, Dashti-Khavidaki S, Shoormasti RS, Pourpak Z (2021) A pilot study on controlling coronavirus disease 2019 (COVID-19) inflammation using melatonin supplement. Iran (remove . ) J. Allergy Asthma Immunol. 20: 494–499, doi:10.18502/ijaai.v20i4.6959.
10. Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, Rezaie E, Ghaleh HEG, Aghamollaei H, Fasihi-ramandi M, et al. (2021) Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial. Arch. Med. Res. S0188-4409 (21): 00141-7. doi: 10.1016/j.arcmed.2021.06.006 doi:10.1016/J.ARCMED.2021.06.006.
11. Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Shamshirian A (2022) Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. J. Med. Virol. 94: 263–271. doi:10.1002/JMV.27312.
12. Reiter RJ, Sharma R, Ma Q, Dominquez-Rodriguez A, Marik PE, Abreu-Gonzalez P (2020) Melatonin inhibits COVID-19-induced cytokine storm by reversing aerobic glycolysis in immune cells: A mechanistic analysis. Med. drug Discov., 6: 100044, doi:10.1016/j.medidd.2020.100044.
13. Tan DX, Hardeland R (2020) Potential utility of melatonin in deadly infectious diseases related to the overreaction of innate immune response and destructive inflammation: focus on COVID-19. Melatonin Res. 3: 120–143, doi:10.32794/mr11250052.
14. Cardinali DP, Brown GM, Pandi-Perumal SR (2020) Can melatonin be a potential “silver bullet” in treating COVID-19 patients? Dis. (Basel, Switzerland), 8: 44, doi:10.3390/DISEASES8040044.
15. Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A (2020) Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19. Front. Med. 7: doi:10.3389/FMED.2020.00226.
16. Tan DX, Hardeland R (2020) Targeting host defense system and rescuing compromised mitochondria to increase tolerance against pathogens by melatonin may impact outcome of deadly virus infection pertinent to COVID-19. Molecules 25: (19): 4410doi:10.3390/MOLECULES25194410.
17. Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COVTM (casirivimab and imdevimab) Antibody Cocktail Regeneron Pharmaceuticals Inc. Available online: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-us-government-agreement-purchase (accessed on Nov 24, 2021).
18. Gilead’s coronavirus treatment remdesivir to cost $3,120 for U.S. insured patients Available online: https://www.cnbc.com/2020/06/29/gileads-coronavirus-treatment-remdesivir-to-cost-3120-for-us-insured-patients.html (accessed on Nov 24, 2021).
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Melatonin Res., copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper credit.
In exceptional circumstances articles may be licensed differently. If you have specific condition (such as one linked to funding) that does not allow this license, please mention this to the editorial office of the journal at submission. Exceptions will be granted at the discretion of the publisher.
